In 2024, based on the COMPASSION-15 study results, cadonilimab in combination with chemotherapy was approved in China for the first-line treatment of gastric cancer, demonstrating benefit across all ...

Akeso’s cadonilimab has outperformed the activity of the current standard of care (SoC) treatment option during a real-world study in first-line gastric or gastroesophageal cancer. The AK104-302 trial ...

HONG KONG, Jan. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium ...

Continuation of serplulimab-based therapy beyond first progression in advanced gastric/gastroesophageal junction (G/GEJ) cancer: Preliminary results from the SCAFIGC trial. This is an ASCO Meeting ...

- China has the highest number of cases and deaths from gastric cancer of any country worldwide 1 - - Zolbetuximab is the first and only therapy approved in China to target claudin 18.2, a biomarker ...

Cadonilimab has been included in the 2025 CSCO Gastric Cancer Guidelines as the only Category I recommendation (Level 1A evidence) for first-line immunotherapy, regardless of PD-L1 expression, and is ...

Kohei Shitara, MD, discusses CLDN18.2-guided therapy, nivolumab plus zolbetuximab, and toxicity management in advanced gastric and gastroesophageal cancers. Emerging phase 2 data are helping refine ...

Promising new approaches to treating gastric cancer have emerged in recent years. These treatments aim to increase patient survival, with reduced toxicity and fewer side effects. Immunotherapies work ...

I-Mab has pivoted to focus on givastomig for gastric cancer after divesting its original China portfolio and revamping leadership. Givastomig shows superior early efficacy versus rivals, with ...

On Wednesday, Amgen Inc. (NASDAQ:AMGN) and its partner Zai Lab (NASDAQ:ZLAB) said the final analysis of the Phase 3 FORTITUDE-101 trial evaluating bemarituzumab in combination with chemotherapy ...

These low and negative PD-L1 patients constitute well more than half of the total gastric cancer patient population. In 2024, the FDA narrowed the indication for all approved PD-1 inhibitors in the ...